Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Rafael Alexander Leiva"'
Autor:
Karl Trygve Druckrey-Fiskaaen, Jørn Henrik Vold, Tesfaye Madebo, Håvard Midgard, Olav Dalgard, Rafael Alexander Leiva, Lars T. Fadnes, for the INTRO-HCV Study Group
Publikováno v:
Substance Abuse Treatment, Prevention, and Policy, Vol 19, Iss 1, Pp 1-11 (2024)
Abstract Background Persons with opioid use disorders (OUD) and persons with substance use disorders (SUD) who inject substances have a reduced life expectancy of up to 25 years compared with the general population. Chronic liver diseases are a subst
Externí odkaz:
https://doaj.org/article/d694804c641d46cd8db40f37ed00b3e0
Autor:
Lars T Fadnes, Christer Frode Aas, Jørn Henrik Vold, Rafael Alexander Leiva, Christian Ohldieck, Fatemeh Chalabianloo, Svetlana Skurtveit, Ole Jørgen Lygren, Olav Dalgård, Peter Vickerman, Håvard Midgard, Else-Marie Løberg, Kjell Arne Johansson, INTRO-HCV Study Group
Publikováno v:
PLoS Medicine, Vol 18, Iss 6, p e1003653 (2021)
BackgroundThe standard pathways of testing and treatment for hepatitis C virus (HCV) infection in tertiary healthcare are not easily accessed by people who inject drugs (PWID). The aim of this study was to evaluate the efficacy of integrated treatmen
Externí odkaz:
https://doaj.org/article/9bb6e6612a1840878acf19b5da6099cb
Autor:
Lars T. Fadnes, Christer Frode Aas, Jørn Henrik Vold, Christian Ohldieck, Rafael Alexander Leiva, Fatemeh Chalabianloo, Svetlana Skurtveit, Ole Jørgen Lygren, Olav Dalgård, Peter Vickerman, Håvard Midgard, Else-Marie Løberg, Kjell Arne Johansson, for the INTRO-HCV Study Group
Publikováno v:
BMC Infectious Diseases, Vol 19, Iss 1, Pp 1-9 (2019)
Abstract Background A large proportion of people who inject drugs (PWID) living with hepatitis C virus (HCV) infection have not been treated. It is unknown whether inclusion of HCV diagnostics and treatment into integrated substance use disorder trea
Externí odkaz:
https://doaj.org/article/f93b58bba1bd4b6d945e93e634afac23
Autor:
Jørn Henrik Vold, Christer Aas, Rafael Alexander Leiva, Peter Vickerman, Fatemeh Chalabianloo, Else-Marie Løberg, Kjell Arne Johansson, Lars Thore Fadnes
Publikováno v:
BMC Infectious Diseases, Vol 19, Iss 1, Pp 1-15 (2019)
Abstract Background Various integrated care models have been used to improve treatment completion of medications for chronic hepatitis B virus (HBV), chronic hepatitis C virus (HCV), Mycobacterium tuberculosis (TB), and Human immunodeficiency virus (
Externí odkaz:
https://doaj.org/article/09572f70eaff4668839b2821a05ee43b
Autor:
Hrvoje Miletic, Paul Christoffer Lindemann, Karin Collett, Rafael Alexander Leiva, Knut Håkon Bakke, Anna Kristine Myrmel Sæle
Publikováno v:
Clinical Neuropathology. 38:80-83
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::af0b2c635260cb9798cfc36718aac38f
https://doi.org/10.5414/np301140
https://doi.org/10.5414/np301140
Autor:
Svetlana Skurtveit, Christian Ohldieck, Olav Dalgard, Rafael Alexander Leiva, Peter Vickerman, Else-Marie Løberg, Lars Thore Fadnes, Jørn Henrik Vold, Håvard Midgard, Ole Jørgen Scheie Lygren, Kjell Arne Johansson, Fatemeh Chalabianloo, Christer Frode Aas
Publikováno v:
Nature Methods
Fadnes, L T, Aas, C F, Vold, J H, Leiva, R A, Ohldieck, C, Chalabianloo, F, Skurtveit, S, Lygren, O J, Dalgård, O, Vickerman, P T, Midgard, H, Løberg, E M, Johansson, K A & Lim, A G 2021, ' Integrated treatment of hepatitis C virus infection among people who inject drugs : A multicenter randomized controlled trial (INTRO-HCV) ', PLoS Medicine, vol. 18, no. 6, 1003653 . https://doi.org/10.1371/journal.pmed.1003653
PLoS Medicine
e1003653
Plos Medicine
PLoS Medicine, Vol 18, Iss 6, p e1003653 (2021)
Fadnes, L T, Aas, C F, Vold, J H, Leiva, R A, Ohldieck, C, Chalabianloo, F, Skurtveit, S, Lygren, O J, Dalgård, O, Vickerman, P T, Midgard, H, Løberg, E M, Johansson, K A & Lim, A G 2021, ' Integrated treatment of hepatitis C virus infection among people who inject drugs : A multicenter randomized controlled trial (INTRO-HCV) ', PLoS Medicine, vol. 18, no. 6, 1003653 . https://doi.org/10.1371/journal.pmed.1003653
PLoS Medicine
e1003653
Plos Medicine
PLoS Medicine, Vol 18, Iss 6, p e1003653 (2021)
Background The standard pathways of testing and treatment for hepatitis C virus (HCV) infection in tertiary healthcare are not easily accessed by people who inject drugs (PWID). The aim of this study was to evaluate the efficacy of integrated treatme
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4083ee7e462ccc1aa36cac585b65f08f
https://hdl.handle.net/11250/3009523
https://hdl.handle.net/11250/3009523
Autor:
Christer Frode Aas, Lars Thore Fadnes, Kjell Arne Johansson, Ingvild Odsbu, Svetlana Skurtveit, Jørn Henrik Vold, Peter Vickerman, Fatemeh Chalabianloo, Jan Magnus Økland, Rafael Alexander Leiva
Publikováno v:
BMJ Open
BMJ Open, Vol 10, Iss 8 (2020)
Aas, C F, Vold, J H, Skurtveit, S, Odsbu, I, Chalabianloo, F, Økland, J M, Leiva, R A M, Vickerman, P, Johansson, K A & Fadnes, L T 2020, ' On the path towards universal coverage of hepatitis C treatment among people receiving opioid agonist therapy (OAT) in Norway : a prospective cohort study from 2013 to 2017 ', BMJ Open, vol. 10, no. 8, e036355 . https://doi.org/10.1136/bmjopen-2019-036355
e036355
BMJ Open, Vol 10, Iss 8 (2020)
Aas, C F, Vold, J H, Skurtveit, S, Odsbu, I, Chalabianloo, F, Økland, J M, Leiva, R A M, Vickerman, P, Johansson, K A & Fadnes, L T 2020, ' On the path towards universal coverage of hepatitis C treatment among people receiving opioid agonist therapy (OAT) in Norway : a prospective cohort study from 2013 to 2017 ', BMJ Open, vol. 10, no. 8, e036355 . https://doi.org/10.1136/bmjopen-2019-036355
e036355
ObjectivesWe aimed to calculate cumulative hepatitis C virus (HCV) treatment coverage among individuals enrolled in opioid agonist therapy (OAT) in Norway between 2013 and 2017 and to document the treatment transition to direct-acting antiviral (DAA)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bc16f52ec9418bc2f8d067386e6a66e6
https://pubmed.ncbi.nlm.nih.gov/32847908
https://pubmed.ncbi.nlm.nih.gov/32847908
Autor:
Renate Prinzing, Eliav Barr, Ernest Asante-Appiah, Jan Sperl, Klára Werling, Jan Gerstoft, Juan Ignacio Arenas Ruiz-Tapiador, Heather L. Platt, Edita Kazenaite, Petr Urbánek, Seyfettin Köklü, Ligita Jancoriene, Jingjun Qiu, Hege Kileng, Janice Wahl, Waldemar Halota, Robert Flisiak, Bach-Yen Nguyen, Rafael Alexander Leiva, Anca Streinu-Cercel, Gabor Horvath, S. Patel
Publikováno v:
Journal of Hepatology. 65:1112-1119
Direct-acting antiviral agents have improved treatment outcomes for patients with hepatitis C virus (HCV) infection; however, head-to-head comparisons are limited. The C-EDGE Head-2-Head Study compared the safety and efficacy of elbasvir/grazoprevir
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::446bae08bcc62de4537e18cfcdcc180c
https://doi.org/10.1016/j.jhep.2016.07.050
https://doi.org/10.1016/j.jhep.2016.07.050
Autor:
Else-Marie Løberg, Kjell Arne Johansson, Jørn Henrik Vold, Rafael Alexander Leiva, Christer Frode Aas, Fatemeh Chalabianloo, Lars Thore Fadnes, Peter Vickerman
Publikováno v:
BMC Infectious Diseases
BMC Infectious Diseases, Vol 19, Iss 1, Pp 1-15 (2019)
BMC Infectious Diseases, Vol 19, Iss 1, Pp 1-15 (2019)
Background Various integrated care models have been used to improve treatment completion of medications for chronic hepatitis B virus (HBV), chronic hepatitis C virus (HCV), Mycobacterium tuberculosis (TB), and Human immunodeficiency virus (HIV) amon
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2e6f8c75d1f6446d6acb476f13cec02d
https://doi.org/10.1186/s12879-019-3918-2
https://doi.org/10.1186/s12879-019-3918-2
Autor:
Helge Kolstad, Rafael Alexander Leiva, Henning Onarheim, Dorthea Hagen Oma, Haima Mylvaganam, Arnfinn Sundsfjord, Ørjan Samuelsen, Ragnvald Ljones Brekke
Publikováno v:
Tidsskrift for Den norske legeforening. 136:1228-1232
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::95d20a184f62633296d507f432da4b6f
https://doi.org/10.4045/tidsskr.15.1208
https://doi.org/10.4045/tidsskr.15.1208